#United States #biopharmaceuticals #Investor Conferences #Bridgewater #Insmed

Insmed's Upcoming Investor Conferences: A Spotlight on Innovation

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical leader dedicated to improving patient outcomes through groundbreaking therapies, has proclaimed its attendance at two significant investor conferences later this year. These events will enable the company to share insights into its progressive developments in treatments for serious diseases, particularly in the realms of chronic pulmonary and inflammatory conditions.

The first of these conferences will be the Jefferies Global Healthcare Conference, set to take place in London on November 18, 2025, starting at 8:30 AM GMT / 3:30 AM EST. This prominent gathering often attracts investors and stakeholders eager to learn about advancements in the healthcare sector and explore investment opportunities in thriving biopharmaceutical enterprises. Insmed's management is expected to deliver a comprehensive overview of its unique drug therapies and pipeline innovations.

Shortly thereafter, Insmed will also be featured at the Evercore 8th Annual Healthcare Conference on December 2, 2025, in Coral Gables, Florida, at 11:15 AM EST. With this gathering focusing specifically on healthcare investing, it provides an ideal platform for Insmed to discuss its robust research initiatives and commitment to addressing the unmet needs of patients.

Both conferences will be available through live webcasts, accessible via Insmed's investor relations webpage at www.insmed.com. For those unable to attend in real-time, recordings of the presentations will be archived for 30 days, ensuring that all interested parties have the opportunity to catch up on the essential presentations and discussions.

About Insmed

Insmed Incorporated operates with a mission centered around patient well-being. It presents a rich portfolio filled with both approved and investigational therapies aimed at transforming lives affected by debilitating conditions. Currently, Insmed is particularly focused on chronic lung diseases, having secured approval for innovative treatment options that alleviate chronic, debilitating symptoms for patients.

Moreover, the company has embarked on ambitious research endeavors, embracing cutting-edge methods and technologies including gene therapy, AI-driven protein engineering, and protein manufacturing, ensuring that it remains at the forefront of biopharmaceutical advancements. Its dedication to research highlights not only its innovative spirit but also its commitment to addressing the most pressing healthcare challenges.

Headquartered in Bridgewater, New Jersey, Insmed emphasizes community and collaboration in its corporate culture, earning accolades as one of the premier employers in the biotech arena. It has notably maintained a top position on the Science Top Employers list for five successive years, underscoring its reputation as a desirable workplace for professionals in the scientific and healthcare fields.

The upcoming presentations will provide an invaluable opportunity for investors and the broader community to gain insight into the strategic direction of Insmed and the groundbreaking therapies that are on the horizon. For anyone interested in the future of biopharmaceutical advancements and the transformative power of innovative therapies, these conferences promise to be unmissable events.

For continuous updates and news, follow Insmed on LinkedIn, Instagram, YouTube, and X, or check out their website to gain further insights into their journey toward creating life-changing therapies that underscore their commitment to both patients and the broader healthcare landscape.